Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Background: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 was associated with increased reactogenicity and red...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Hum Vaccin Immunother
Päätekijät: Peterson, James T., Stacey, Helen L., MacNair, John E., Li, Jianing, Hartzel, Jonathan S., Sterling, Tina M., Benner, Patrice, Tamms, Gretchen M., Musey, Luwy K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605723/
https://ncbi.nlm.nih.gov/pubmed/30427749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1532250
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia